What Transformation Has the Kidney Cancer Diagnostics And Therapeutics Market Undergone?
The kidney cancer diagnostics and therapeutics market has seen considerable growth due to a variety of factors.
•The dimensions of the kidney cancer diagnostics and therapeutics market have seen substantial expansion in the past few years. The market, which was valued at $4.1 billion in 2024, is projected to reach $4.32 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 5.4%.
The upsurge witnessed in the historical period can be traced back to factors such as advancements in molecular biology research, clinical trials and drug development, surgical innovations, genetic breakthroughs, and enhancements in healthcare access.
How Will The Kidney Cancer Diagnostics And Therapeutics Market Size Evolve In The Foreseeable Future?
The kidney cancer diagnostics and therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The market for kidney cancer diagnostics and therapeutics is anticipated to witness a robust expansion in the coming years, reaching $5.68 billion in 2029 with a CAGR of 7.0%.
This anticipated growth during the forecast period is due to factors such as progress in biomarker research, breakthroughs in genomic sequencing, proliferation of telemedicine and remote consultations, to name a few. Additionally, advancements in precision medicine and the speedy development of diagnostic technologies also contribute to this growth. Key trends to watch during this period include the incorporation of palliative care, care for long-term survivors, intervention in nutrition and lifestyle, wider use of radiomics and adoption of liquid biopsies.
What Are The Essential Drivers Behind The Growth Of The Kidney Cancer Diagnostics And Therapeutics Market?
The escalating incidence of kidney cancer is predicted to fuel the expansion of the kidney cancer diagnostics and therapeutics market. The disease, kidney cancer, occurs when the ordinarily functioning cells in either or both kidneys undergo abnormal alterations, leading to unrelenting growth, and creating a mass known as a renal cortical tumor. Diagnostics and therapeutics for kidney cancer are essential in the disease's control and treatment, providing numerous advantages for patients, such as early detection, precise diagnosis, treatment selection, personalized medicine, and treatment monitoring. For example, the American Society of Clinical Oncology (ASCO), a US-based non-profit organization devoted to cancer care, reported in March 2023 that in the United States, kidney cancer would be found in 81,800 individuals (52,360 males and 29,440 females) in 2023. Furthermore, kidney cancer is reported to have afflicted 431,288 individuals on a global scale in 2020. Consequently, the rising incidence of kidney cancer is anticipated to stimulate the growth of the kidney cancer diagnostics and therapeutics market.
How Is The Global Kidney Cancer Diagnostics And Therapeutics Market Divided Into Key Segments?
The kidney cancer diagnostics and therapeutics market covered in this report is segmented –
1) By Cancer Type: Clear Cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma And Transitional Cell Carcinoma, Other Cancer Types
2) By Component: Drugs, Diagnostics
3) By Diagnostics: Biopsy, CT Scan, Nephro-Ureteroscopy, Intravenous Pyelogram, Ultrasound
4) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy
5) By End-Users: Hospitals, Pharmaceutical Labs, Genomics Laboratories
Subsegments:
1) By Clear Cell RCC: Stage I, Stage II, Stage III, Stage IV
2) By Papillary RCC: Type 1, Type 2
3) By Chromophobe RCC: Localized, Advanced
4) By Urothelial Carcinoma And Transitional Cell Carcinoma: Non-muscle invasive, Muscle invasive, Metastatic
5) By Other Cancer Types: Collecting Duct Carcinoma, Renal Medullary Carcinoma, Other rare types
Pre-Book The Kidney Cancer Diagnostics And Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Kidney Cancer Diagnostics And Therapeutics Market?
Dominant companies in the kidney cancer diagnostics and therapeutics industry are concentrating on the progression of advanced renal cell carcinoma (RCC) strategies to enhance patient outcomes and supply innovative treatment options designed to cater to the unique requirements of individuals identified with this complex disease. Investigations into renal cell carcinoma (RCC) are critical for the kidney cancer diagnostics and therapeutics sector, as they prompt the development of inventive diagnostic procedures and targeted therapies that enhance early detection and personalized treatment for patients. For instance, Merck, a pharmaceutical corporation based in the US, launched welireg (belzutifan), the initial hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor approved for adult patients with advanced renal cell carcinoma (RCC), in December 2023 after prior PD-1 or PD-L1 inhibitors and VEGF-TKIs treatments. This new therapeutic category demonstrates substantial advantages, including enhanced progression-free survival and elevated response rates compared to everolimus. The authorization of WELIREG signifies a critical progress in the kidney cancer diagnostics and therapeutics market, providing new optimism for patients with advancing disease.
Who Are the Key Players in the Kidney Cancer Diagnostics And Therapeutics Market?
Major companies operating in the kidney cancer diagnostics and therapeutics market include:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A
• Bristol-Myers Squibb Pharmaceuticals Limited
• Thermo Fisher Scientific Inc.
• AstraZeneca PLC
• Abbott Laboratories
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Co Ltd.
• Amgen Inc.
• Siemens Healthcare GmbH
• Laboratory Corporation of America Holdings
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Illumina Inc.
• PerkinElmer Inc.
• Ipsen S.A
• Bio-Rad Laboratories Inc.
• QIAGEN NV
• Exelixis Inc.
• Myriad Genetics Inc.
• Invitae Corporation
• Guardant Health Inc.
• GeneDx LLC
• CD Genomics
• Genpath Life Sciences Private Limited
What are the Regional Insights into the Kidney Cancer Diagnostics And Therapeutics Market?
North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
